Advanced or Metastatic Solid Tumors Clinical Trial
Official title:
A Phase 1/2, Open-Label, Multicenter Study of MDK-703 as a Monotherapy and in Combination With Other Anti-Cancer Therapies in Patients With Advanced or Metastatic Solid Tumors (ORCHID-1)
This is an open-label, dose escalation and dose expansion study of MDK-703 as a monotherapy and in combination with other cancer therapies in adult study participants with advanced or metastatic solid tumors.
This is a Phase 1/2, open-label, multicenter, dose escalation and dose expansion study evaluating MDK-703 in adult study participants with advanced or metastatic solid tumors. This study will initially commence with dose escalation to evaluate the safety/tolerability of MDK-703 as a monotherapy and in combination with other cancer therapies. Once the monotherapy and/or combination therapy maximum tolerated dose (MTD), optimal biological dose (OBD), and/or recommended dose (RD) has been determined, then dose expansion of MDK-703 may commence in select populations of interest. The study will also evaluate the anti-tumor activity and pharmacokinetic (PK) and pharmacodynamic (PD) profiles of MDK-703 as a monotherapy and in combination with other cancer therapies. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT05017012 -
A Study to Evaluate the Bioavailability of Pembrolizumab (MK-3475) Via Subcutaneous (SC) Injection of MK-3475A (Pembrolizumab Formulated With MK-5180) In Advanced Solid Tumors (MK-3475A-C18)
|
Phase 1 | |
| Completed |
NCT02261532 -
A Phase I Study of TAS-102 in Solid Tumors
|
Phase 1 | |
| Completed |
NCT00748553 -
A Phase I/II Clinical Trial of Vidaza With Abraxane in the Treatment of Patients With Advanced or Metastatic Solid Tumors and Breast Cancer
|
Phase 1/Phase 2 | |
| Completed |
NCT03248843 -
A Study of PD-L1 Antibody KN035 in Japanese Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT05572684 -
A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
| Terminated |
NCT04003623 -
Efficacy and Safety of Pemigatinib in Participants With Solid Tumors With FGFR Mutations or Translocations (FIGHT-208)
|
Phase 2 | |
| Terminated |
NCT05496595 -
DCBY02 as a Monotherapy in Patients With Advanced or Metastatic Solid Tumors
|
Phase 1 | |
| Active, not recruiting |
NCT01928394 -
A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
| Terminated |
NCT01506934 -
A Study Evaluating the Bioavailability of Two Formulations of Linifanib and Food Effect on Pharmacokinetics of Linifanib in Subjects With Advanced or Metastatic Solid Tumors
|
Phase 1 | |
| Completed |
NCT03730337 -
Phase 1 Study of ONO-7475 With and Without ONO-4538 in Subjects Advanced or Metastatic Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT04586270 -
A Study of TAS0612 in Participants With Advanced or Metastatic Solid Tumor Cancer
|
Phase 1 | |
| Recruiting |
NCT06248411 -
A Clinical Study of KK2260 in Patients With Advanced or Metastatic Solid Tumors
|
Phase 1 | |
| Not yet recruiting |
NCT06389526 -
A Study of CHS-1000 in Participants With Advanced or Metastatic Solid Tumors
|
Phase 1 | |
| Completed |
NCT03665285 -
A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT05957081 -
Study to Assess the Safety, Tolerability, and Blood Concentration of PMC-309
|
Phase 1 | |
| Active, not recruiting |
NCT03316638 -
A Study of a New Investigational Medicinal Product to Treat Patients With Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
| Terminated |
NCT01355302 -
E7050 in Combination With Cisplatin and Capecitabine Versus Cisplatin and Capecitabine Alone in Patients With Advanced or Metastatic Solid Tumors and Previously Untreated Gastric Cancer
|
Phase 1/Phase 2 | |
| Completed |
NCT01014429 -
Study of NMS-1286937 in Adult Patients With Advanced/Metastatic Solid Tumors
|
Phase 1 | |
| Not yet recruiting |
NCT06074497 -
A Phase 1, First-in-Human of KGX101 to Patients With Advanced or Metastatic Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT06448364 -
A Study in Advanced/Metastatic Solid Tumors With the Study Medicine (PF-07329640) When Given Alone or In Combination
|
Phase 1 |